Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
17
STIM Quote, Financials, Valuation and Earnings
Last price:
$3.76
Seasonality move
:
-4.17%
Day range:
$3.75 - $4.06
52-week range:
$0.52 - $5.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.60x
P/B ratio:
8.98x
Volume:
2.1M
Avg. volume:
1.5M
1-year change:
-21.41%
Market cap:
$248.8M
Revenue:
$74.9M
EPS (TTM):
-$1.37
Analysts' Opinion
-
Consensus RatingNeuronetics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.83, Neuronetics has an estimated upside of 80.78% from its current price of $3.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.50 representing 100% downside risk from its current price of $3.78.
Fair Value
-
According to the consensus of 2 analysts, Neuronetics has 80.78% upside to fair value with a price target of $6.83 per share.
STIM vs. S&P 500
-
Over the past 5 trading days, Neuronetics has underperformed the S&P 500 by -12.58% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Neuronetics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neuronetics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Neuronetics reported revenues of $22.5M.
Earnings Growth
-
Neuronetics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Neuronetics reported earnings per share of -$0.33.
Enterprise value:
289.4M
EV / Invested capital:
--
Price / LTM sales:
1.60x
EV / EBIT:
--
EV / Revenue:
3.86x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-8.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$54.2M
Return On Assets:
-41.12%
Net Income Margin (TTM):
-58.36%
Return On Equity:
-178.53%
Return On Invested Capital:
-54.36%
Operating Margin:
-51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $65.2M | $71.3M | $74.9M | $20.3M | $22.5M | |
| Gross Profit | $49.7M | $51.7M | $54.2M | $15.8M | $14.9M | |
| Operating Income | -$35.1M | -$30.6M | -$34.6M | -$4.4M | -$11.5M | |
| EBITDA | -$32M | -$23.4M | -$35.2M | -$3.6M | -$11.3M | |
| Diluted EPS | -$1.38 | -$1.07 | -$1.37 | -$0.19 | -$0.33 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65M | $115.3M | $98.8M | $93.8M | $58.1M | |
| Total Assets | $78.7M | $141.2M | $116.9M | $115.8M | $140.9M | |
| Current Liabilities | $13.7M | $15.7M | $33.2M | $19.8M | $31.3M | |
| Total Liabilities | $53.2M | $56M | $59.8M | $81.6M | $109.1M | |
| Total Equity | $25.5M | $85.2M | $57.1M | $34.2M | $31.8M | |
| Total Debt | $34.6M | $35.3M | $36M | $59.3M | $55.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.7M | -$32M | -$31M | $2.1M | -$8.6M | |
| Cash From Investing | $6.7M | -$1.3M | -$2.4M | -$563K | -$2.4M | |
| Cash From Financing | $207K | $22.7M | -$6.8M | $22.3M | $9.6M | |
| Free Cash Flow | -$34M | -$34.4M | -$32.5M | $1.3M | -$8.7M | |
STIM
Sector
Market Cap
$248.8M
$37M
Price % of 52-Week High
63.85%
43.14%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
-21.41%
-43.58%
Beta (5-Year)
1.975
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.15
200-day SMA
Buy
Level
$1.95
Bollinger Bands (100)
Buy
Level
1.07 - 4.11
Chaikin Money Flow
Sell
Level
-61.2M
20-day SMA
Sell
Level
$4.59
Relative Strength Index (RSI14)
Sell
Level
41.37
ADX Line
Sell
Level
28.89
Williams %R
Buy
Level
-82.9787
50-day SMA
Sell
Level
$3.96
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
78.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.79)
Sell
CA Score
(Annual)
Level (-2.7329)
Sell
Beneish M-Score
(Annual)
Level (-1.3972)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.2279)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Stock Forecast FAQ
In the current month, STIM has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The STIM average analyst price target in the past 3 months is $6.83.
-
Where Will Neuronetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neuronetics share price will rise to $6.83 per share over the next 12 months.
-
What Do Analysts Say About Neuronetics?
Analysts are divided on their view about Neuronetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neuronetics is a Sell and believe this share price will drop from its current level to $5.50.
-
What Is Neuronetics's Price Target?
The price target for Neuronetics over the next 1-year time period is forecast to be $6.83 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is STIM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neuronetics is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of STIM?
You can purchase shares of Neuronetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neuronetics shares.
-
What Is The Neuronetics Share Price Today?
Neuronetics was last trading at $3.76 per share. This represents the most recent stock quote for Neuronetics. Yesterday, Neuronetics closed at $3.78 per share.
-
How To Buy Neuronetics Stock Online?
In order to purchase Neuronetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
100
DLICY alert for Apr 2
Dai-ichi Life Holdings [DLICY] is up 100.91% over the past day.
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Sell
15
PCVX alert for Apr 2
Vaxcyte [PCVX] is down 14.62% over the past day.
